CARD for Community Pharmacy Vaccinations - Phase 2
Launched by UNIVERSITY OF TORONTO · Oct 29, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The CARD for Community Pharmacy Vaccinations study is researching a program called the Comfort Ask Relax System (CARD) that aims to make getting vaccinated easier and more comfortable for patients. This is the second phase of the trial, where some community pharmacies will continue using CARD, while others that were not part of the program in the first phase will start using it. This study is particularly focused on how well CARD helps reduce pain and reactions during vaccinations in the upcoming fall and winter vaccination seasons of 2024-2025.
To participate in this study, individuals must be getting vaccinated at one of the participating pharmacies. This includes both patients receiving vaccinations and the pharmacy staff giving them. One important note is that participants should be able to speak and write in English. Although the study is not actively recruiting participants yet, it will eventually help improve the vaccination experience for everyone involved by making it more comfortable and effective.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • clients undergoing vaccination in participating pharmacies and providers working in participating pharmacies
- Exclusion Criteria:
- • able to speak and write in English
About University Of Toronto
The University of Toronto, a prestigious research institution, serves as a leading sponsor of clinical trials dedicated to advancing medical knowledge and improving patient care. With a commitment to innovation and excellence, the university fosters a collaborative environment that brings together multidisciplinary teams of experts in medicine, pharmacology, and public health. Through rigorous research methodologies and ethical standards, the University of Toronto aims to explore new therapies, assess treatment efficacy, and address critical health challenges, ultimately contributing to the global body of scientific knowledge and enhancing healthcare outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Anna Taddio, PhD
Principal Investigator
Leslie Dan Faculty Of Pharmacy, University Of Toronto
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported